EP1492508A4 - DOSAGE FORMS WITH CONTROLLED RELEASE - Google Patents

DOSAGE FORMS WITH CONTROLLED RELEASE

Info

Publication number
EP1492508A4
EP1492508A4 EP03713882A EP03713882A EP1492508A4 EP 1492508 A4 EP1492508 A4 EP 1492508A4 EP 03713882 A EP03713882 A EP 03713882A EP 03713882 A EP03713882 A EP 03713882A EP 1492508 A4 EP1492508 A4 EP 1492508A4
Authority
EP
European Patent Office
Prior art keywords
dosage forms
controlled release
release dosage
controlled
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03713882A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1492508A1 (en
Inventor
E Itzhak Lerner
Vered Rosenberger
Ofer Aqua
Moshe Flashner-Barak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1492508A1 publication Critical patent/EP1492508A1/en
Publication of EP1492508A4 publication Critical patent/EP1492508A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets
EP03713882A 2002-03-04 2003-03-03 DOSAGE FORMS WITH CONTROLLED RELEASE Withdrawn EP1492508A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US291619 1994-08-17
US36182102P 2002-03-04 2002-03-04
US361821P 2002-03-04
US29161902A 2002-11-12 2002-11-12
PCT/US2003/006591 WO2003075893A1 (en) 2002-03-04 2003-03-03 Controlled release dosage forms

Publications (2)

Publication Number Publication Date
EP1492508A1 EP1492508A1 (en) 2005-01-05
EP1492508A4 true EP1492508A4 (en) 2009-05-06

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03713882A Withdrawn EP1492508A4 (en) 2002-03-04 2003-03-03 DOSAGE FORMS WITH CONTROLLED RELEASE

Country Status (13)

Country Link
EP (1) EP1492508A4 (zh)
JP (1) JP2005524670A (zh)
KR (1) KR20100049695A (zh)
CN (1) CN1649569B (zh)
AU (2) AU2003217909C1 (zh)
BR (1) BR0308305A (zh)
CA (1) CA2477701A1 (zh)
EA (1) EA005866B1 (zh)
IL (1) IL163887A0 (zh)
MX (1) MXPA04008536A (zh)
NO (1) NO20044188L (zh)
NZ (1) NZ535083A (zh)
WO (1) WO2003075893A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
CN1681493A (zh) * 2002-07-19 2005-10-12 兰贝克赛实验室有限公司 掩味舒马曲坦片剂及其制备方法
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
CN1738600A (zh) * 2002-11-12 2006-02-22 特瓦制药工业有限公司 用于口腔给药和舌下给药的替扎尼定药物组合物及剂型以及舌下或口腔给予替扎尼定的方法
ES2618781T3 (es) * 2003-11-14 2017-06-22 Sanwa Kagaku Kenkyusho Co., Ltd. Procedimiento de fabricación de un moldeado nucleado
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CA2555406A1 (en) * 2004-02-19 2005-09-01 Teva Pharmaceutical Industries, Ltd. Improved therapy using a combination of raloxifene and alendronate
KR100701409B1 (ko) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 호박산 수마트립탄을 함유하는 약제학적 조성물
AU2009281752B2 (en) 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
CN110368371A (zh) * 2014-04-08 2019-10-25 越洋医药开发(广州)有限公司 一种新型控释片
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
CN110604724A (zh) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 一种肠溶美沙拉秦缓释片剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
EP0205342A2 (en) * 1985-06-11 1986-12-17 Pitman-Moore Limited Agent delivery systems
WO1996019201A1 (en) * 1994-12-22 1996-06-27 Merck & Co., Inc. A controlled release drug suspension delivery device

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61243016A (ja) * 1985-04-19 1986-10-29 Katsumi Takada 柱状の有効成分含有部分をもつ錠剤
JPS6253918A (ja) * 1985-09-02 1987-03-09 Katsumi Takada 柱状の有効成分含有部分を埋没させた錠剤
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
JP3962108B2 (ja) * 1995-04-03 2007-08-22 中外製薬株式会社 スクラルファート含有製剤組成物
CA2184316A1 (en) * 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
SI0931543T1 (en) * 1997-12-19 2002-10-31 Merck Patent Gmbh Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria
EP1039908B1 (en) * 1997-12-22 2004-02-25 Schering Corporation Molecular dispersion composition with enhanced bioavailability
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
CA2413816A1 (en) * 2000-06-28 2002-01-03 Angiogenix, Inc. Controlled release arginine formulations
BR0215413A (pt) * 2001-12-24 2004-12-14 Teva Pharma Formula dosada com um comprimido central de ingrediente ativo encapado em uma capa anular prensada de material em pó ou granulado e processo e conjunto de ferramentas para a sua produção

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
EP0205342A2 (en) * 1985-06-11 1986-12-17 Pitman-Moore Limited Agent delivery systems
WO1996019201A1 (en) * 1994-12-22 1996-06-27 Merck & Co., Inc. A controlled release drug suspension delivery device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03075893A1 *

Also Published As

Publication number Publication date
NO20044188L (no) 2004-12-03
NZ535083A (en) 2007-06-29
EA200401097A1 (ru) 2005-04-28
CN1649569B (zh) 2010-05-05
AU2003217909A1 (en) 2003-09-22
CN1649569A (zh) 2005-08-03
WO2003075893A1 (en) 2003-09-18
AU2003217909C1 (en) 2009-06-11
CA2477701A1 (en) 2003-09-18
EP1492508A1 (en) 2005-01-05
KR20100049695A (ko) 2010-05-12
AU2003217909B2 (en) 2008-10-30
JP2005524670A (ja) 2005-08-18
EA005866B1 (ru) 2005-06-30
BR0308305A (pt) 2004-12-28
AU2009200353A1 (en) 2009-02-19
MXPA04008536A (es) 2005-09-08
IL163887A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
TWI347202B (en) Controlled release preparation
IL174343A0 (en) Delayed released dosage forms
AU2003244650A8 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
IL163887A0 (en) Controlled release dosage forms
AU2003215150A8 (en) Therapeutic compounds
AU2003261067A8 (en) Modified release ketoprofen dosage form
AU2003255890A8 (en) Nitrofurantoin controlled release dosage form
GB0208392D0 (en) Therapeutic compounds
AU2003220479A1 (en) Modified release dosage forms
GB0211444D0 (en) Controlled release formulations
GB0215656D0 (en) Controlled release composition
GB0224494D0 (en) Medicinal compounds
GB0215930D0 (en) Medicinal compounds
GB0224508D0 (en) Medicinal compounds
GB0225536D0 (en) Medicinal compounds
GB0225541D0 (en) Medicinal compounds
GB0224502D0 (en) Medicinal compounds
GB0224498D0 (en) Medicinal compounds
GB0228915D0 (en) Medicinal compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1067063

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20090402

RIC1 Information provided on ipc code assigned before grant

Ipc: B30B 11/08 20060101ALI20090327BHEP

Ipc: B29C 43/20 20060101ALI20090327BHEP

Ipc: A61K 9/30 20060101ALI20090327BHEP

Ipc: A61K 9/28 20060101ALI20090327BHEP

Ipc: A61K 9/24 20060101AFI20090327BHEP

17Q First examination report despatched

Effective date: 20090616

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1067063

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121002